Supported by advanced structural biology capabilities at MAX IV, Acrivon Therapeutics advanced a novel cancer drug candidate from initial lead identification to clinical development in only 15 months.
Beamlines
Highlights
ForMAX beamline celebrates 1 year in operations
November 1 marks one year since ForMAX beamline officially opened for user experiments. Congratulations to ForMAX and everyone involved in making ForMAX possible! It has been one exciting first year.